COPN.SW

COSMO Pharmaceuticals SA

COPN.SW, Switzerland

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

https://www.cosmopharma.com

Stock Price

CHF0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
COPN.SW
stock
COPN.SW

Cosmo Pharmaceuticals (SWX:COPN) Is Up 46.9% After Expanding Its Clascoterone Dermatology Franchise Yahoo Finance

Read more →
COPN.SW
stock
COPN.SW

Cosmo Pharmaceuticals (SWX:COPN): Assessing Valuation Following Recent Share Price Momentum Yahoo Finance

Read more →

Showing 2 of 5

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

0

Buy

3

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

19.73

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

3.74

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.44 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3.33 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.31

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of COSMO Pharmaceuticals SA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.13

EPS Estimate

1.3

EPS Difference

-1.43

Surprise Percent

-110%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

CHF 0

Cost Of Revenue

CHF 0

Gross Profit

CHF 0

Operating Expenses

CHF 0

Operating Income

CHF 0

Interest Expense

CHF 0

Pretax Income

CHF 0

Net Income

CHF 0

Income Tax Expense

CHF 0

EBITDA

CHF 0

Total Other Income Expense Net

CHF 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

CHF 0

Short Term Investments

CHF 0

Receivables

CHF 0

Inventories

CHF 0

Total Current Assets

CHF 0

Property Plant Equipment

CHF 0

Total Assets

CHF 0

Payables

CHF 0

Short Term Debt

CHF 0

Long Term Debt

CHF 0

Total Liabilities

CHF 0

Equity

CHF 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

CHF 0

Depreciation

CHF 0

Change In Working Capital

CHF 0

Cash From Operations

CHF 0

Capital Expenditures

CHF 0

Cash From Investing

CHF 0

Cash From Financing

CHF 0

Net Change In Cash

CHF 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.